{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:34:29Z","timestamp":1771472069649,"version":"3.50.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","thespinejournalonline.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Spine Journal"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.spinee.2020.08.013","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T16:17:42Z","timestamp":1598372262000},"page":"1893-1898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Novel therapies for spinal muscular atrophy are likely changing the patient phenotype"],"prefix":"10.1016","volume":"20","author":[{"given":"Tu-Lan","family":"Vu-Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Wei\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Pumberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.spinee.2020.08.013_bib0001","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9","article-title":"An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA)","volume":"15","author":"Wirth","year":"2000","journal-title":"Hum Mutat"},{"issue":"8","key":"10.1016\/j.spinee.2020.08.013_bib0002","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.spinee.2020.08.013_bib0003","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","article-title":"Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next","volume":"21","author":"Wirth","year":"2020","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"3","key":"10.1016\/j.spinee.2020.08.013_bib0004","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1006\/geno.2000.6396","article-title":"The transcription factor-like nuclear regulator (TFNR) contains a novel 55-amino-acid motif repeated nine times and maps closely to SMN1","volume":"70","author":"Kelter","year":"2000","journal-title":"Genomics"},{"issue":"6266","key":"10.1016\/j.spinee.2020.08.013_bib0005","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/344540a0","article-title":"Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3","volume":"344","author":"Brzustowicz","year":"1990","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.spinee.2020.08.013_bib0006","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/nm0295-124","article-title":"Is the spinal muscular atrophy gene found?","volume":"1","author":"Gilliam","year":"1995","journal-title":"Nat Med"},{"issue":"6278","key":"10.1016\/j.spinee.2020.08.013_bib0007","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/345823a0","article-title":"Genetic homogeneity between acute and chronic forms of spinal muscular atrophy","volume":"345","author":"Gilliam","year":"1990","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.spinee.2020.08.013_bib0008","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/00019052-199710000-00005","article-title":"Spinal muscular atrophy","volume":"10","author":"Melki","year":"1997","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"10.1016\/j.spinee.2020.08.013_bib0009","first-page":"892","article-title":"Proximal spinal muscular atrophy (SMA) types II and III in the same sibship are not caused by different alleles at the SMA locus on 5q","volume":"50","author":"Muller","year":"1992","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.spinee.2020.08.013_bib0010","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/nyas.12727","article-title":"Splicing regulation in spinal muscular atrophy by an RNA structure formed by long-distance interactions","volume":"1341","author":"Singh","year":"2015","journal-title":"Ann N Y Acad Sci"},{"issue":"11-12","key":"10.1016\/j.spinee.2020.08.013_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagrm.2019.07.004","article-title":"How RNA structure dictates the usage of a critical exon of spinal muscular atrophy gene","volume":"1862","author":"Singh","year":"2019","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"12","key":"10.1016\/j.spinee.2020.08.013_bib0012","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1212\/WNL.40.12.1831","article-title":"Phenotypic heterogeneity of spinal muscular atrophy mapping to chromosome 5q11.2-13.3 (SMA 5q)","volume":"40","author":"Munsat","year":"1990","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.1016\/j.spinee.2020.08.013_bib0013","first-page":"29","article-title":"Phenotype and genotype correlation in childhood spinal muscular atrophy","volume":"35","author":"Hausmanowa-Petrusewicz","year":"2001","journal-title":"Neurol Neurochir Pol"},{"issue":"5-6","key":"10.1016\/j.spinee.2020.08.013_bib0014","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0960-8966(06)80016-7","article-title":"On chaos in classification of childhood spinal muscular atrophy","volume":"2","author":"Hausmanowa-Petrusewicz","year":"1992","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"10.1016\/j.spinee.2020.08.013_bib0015","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/0883073807305673","article-title":"Spinal muscular atrophy: clinical classification and disease heterogeneity","volume":"22","author":"Russman","year":"2007","journal-title":"J Child Neurol"},{"issue":"5","key":"10.1016\/j.spinee.2020.08.013_bib0016","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","article-title":"Childhood spinal muscular atrophy: controversies and challenges","volume":"11","author":"Mercuri","year":"2012","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.spinee.2020.08.013_bib0017","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCyclerPCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldkotter","year":"2002","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.spinee.2020.08.013_bib0018","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s00439-006-0156-7","article-title":"Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number","volume":"119","author":"Wirth","year":"2006","journal-title":"Hum Genet"},{"issue":"8","key":"10.1016\/j.spinee.2020.08.013_bib0019","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrn2670","article-title":"Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?","volume":"10","author":"Burghes","year":"2009","journal-title":"Nat Rev Neurosci"},{"issue":"18","key":"10.1016\/j.spinee.2020.08.013_bib0020","doi-asserted-by":"crossref","first-page":"9920","DOI":"10.1073\/pnas.94.18.9920","article-title":"Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos","volume":"94","author":"Schrank","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.spinee.2020.08.013_bib0021","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-008-0411-1","article-title":"Pathogenesis of proximal autosomal recessive spinal muscular atrophy","volume":"116","author":"Simic","year":"2008","journal-title":"Acta Neuropathol"},{"issue":"3","key":"10.1016\/j.spinee.2020.08.013_bib0022","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.neulet.2008.10.107","article-title":"The neuroprotective factor Wld(s) fails to mitigate distal axonal and neuromuscular junction (NMJ) defects in mouse models of spinal muscular atrophy","volume":"449","author":"Kariya","year":"2009","journal-title":"Neurosci Lett"},{"issue":"6","key":"10.1016\/j.spinee.2020.08.013_bib0023","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/jmg.33.6.469","article-title":"Unusual molecular findings in autosomal recessive spinal muscular atrophy","volume":"33","author":"Matthijs","year":"1996","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.spinee.2020.08.013_bib0024","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.spinee.2020.08.013_bib0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1086\/513886","article-title":"Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype","volume":"61","author":"Campbell","year":"1997","journal-title":"Am J Hum Genet"},{"issue":"1577","key":"10.1016\/j.spinee.2020.08.013_bib0026","first-page":"113","article-title":"Zolgensma - one-time gene therapy for spinal muscular atrophy","volume":"61","year":"2019","journal-title":"Med Lett Drugs Ther"},{"issue":"5","key":"10.1016\/j.spinee.2020.08.013_bib0027","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1007\/s12325-019-00923-8","article-title":"Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1","volume":"36","author":"Dabbous","year":"2019","journal-title":"Adv Ther"},{"issue":"11","key":"10.1016\/j.spinee.2020.08.013_bib0028","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene abeparvovec: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.spinee.2020.08.013_bib0029","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ana.20548","article-title":"Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells","volume":"58","author":"Grzeschik","year":"2005","journal-title":"Ann Neurol"},{"issue":"1-2","key":"10.1016\/j.spinee.2020.08.013_bib0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jns.2007.11.012","article-title":"The effect of hydroxyurea in spinal muscular atrophy cells and patients","volume":"268","author":"Liang","year":"2008","journal-title":"J Neurol Sci"},{"issue":"10","key":"10.1016\/j.spinee.2020.08.013_bib0031","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/ejhg.2011.89","article-title":"Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter- and intra-patient variability","volume":"19","author":"Also-Rallo","year":"2011","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"10.1016\/j.spinee.2020.08.013_bib0032","first-page":"161","article-title":"Valproate and spinal muscular atrophy (Review)","volume":"1","author":"Natasha","year":"2008","journal-title":"Mol Med Rep"},{"issue":"2","key":"10.1016\/j.spinee.2020.08.013_bib0033","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2017.0665","article-title":"FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther"},{"issue":"10","key":"10.1016\/j.spinee.2020.08.013_bib0034","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"issue":"10063","key":"10.1016\/j.spinee.2020.08.013_bib0035","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.spinee.2020.08.013_bib0036","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0883073815627882","article-title":"Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience","volume":"31","author":"Hache","year":"2016","journal-title":"J Child Neurol"},{"issue":"9","key":"10.1016\/j.spinee.2020.08.013_bib0037","first-page":"e1644","article-title":"Spinal muscular atrophy: the treatment approved","volume":"9","author":"Tabet","year":"2017","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.spinee.2020.08.013_bib0038","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(17)30085-6","article-title":"Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Bertini","year":"2017","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.spinee.2020.08.013_bib0039","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/jpet.114.222224","article-title":"The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure","volume":"353","author":"Hwee","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"issue":"7367","key":"10.1016\/j.spinee.2020.08.013_bib0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.spinee.2020.08.013_bib0041","unstructured":"FDA approves first drug for spinal muscular atrophy. FDA NEWS RELEASE. [updated December 23, 2016; cited 2020 06\/13\/2020]; Available at:https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-spinal-muscular-atrophy. Accessed on May 31st, 2020."},{"issue":"18","key":"10.1016\/j.spinee.2020.08.013_bib0042","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.spinee.2020.08.013_bib0043","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1083\/jcb.201207087","article-title":"Antisense-based therapy for the treatment of spinal muscular atrophy","volume":"199","author":"Rigo","year":"2012","journal-title":"J Cell Biol"},{"issue":"10","key":"10.1016\/j.spinee.2020.08.013_bib0044","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/14737175.2017.1364159","article-title":"Nusinersen for the treatment of spinal muscular atrophy","volume":"17","author":"Chiriboga","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.spinee.2020.08.013_bib0045","unstructured":"First medicine for spinal muscular atrophy. [Press Release] Online: European Medicines Agency. [updated 21\/04\/2017; cited 2020 06\/13\/2020]; Available at: https:\/\/www.ema.europa.eu\/en\/news\/first-medicine-spinal-muscular-atrophy. Accessed on May 1st, 2020."},{"key":"10.1016\/j.spinee.2020.08.013_bib0046","article-title":"Transforaminal intrathecal delivery of nusinersen for older children and adults with spinal muscular atrophy and complex spinal anatomy: an analysis of 200 consecutive injections","author":"Weaver","year":"2020","journal-title":"J Neurointerv Surg"},{"issue":"3","key":"10.1016\/j.spinee.2020.08.013_bib0047","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00247-017-4031-6","article-title":"Transforaminal intrathecal delivery of nusinersen using cone-beam computed tomography for children with spinal muscular atrophy and extensive surgical instrumentation: early results of technical success and safety","volume":"48","author":"Weaver","year":"2018","journal-title":"Pediatr Radiol"},{"issue":"3","key":"10.1016\/j.spinee.2020.08.013_bib0048","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3233\/JND-190453","article-title":"Prospective cohort study of nusinersen treatment in adults with spinal muscular atrophy","volume":"7","author":"Yeo","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.spinee.2020.08.013_bib0049","article-title":"Drug treatment for spinal muscular atrophy types II and III","volume":"1","author":"Wadman","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.spinee.2020.08.013_bib0050","article-title":"Drug treatment for spinal muscular atrophy type I","volume":"12","author":"Wadman","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.spinee.2020.08.013_bib0051","unstructured":"New gene therapy to treat spinal muscular atrophy (corrected). [Press release]: European Medicines Agency EMA. [updated 03\/27\/202006\/13\/2020]; Zolgensma]. Available at: www.ema.europa.eu\/en\/news\/new-gene-therapy-treat-spinal-muscular-atrophy-corrected. Accessed on May 1st, 2020."},{"issue":"6","key":"10.1016\/j.spinee.2020.08.013_bib0052","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s00115-020-00919-8","volume":"91","author":"Ziegler","year":"2020","journal-title":"Nervenarzt"},{"key":"10.1016\/j.spinee.2020.08.013_bib0053","unstructured":"FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality. [FDA News Release]: FDA; 2019[updated 05\/24\/2019; cited 2020 06\/13\/2020]; Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease. Accessed on May 1st, 2020."},{"key":"10.1016\/j.spinee.2020.08.013_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2020.05.044","article-title":"Subacute liver failure following gene replacement therapy for spinal muscular atrophy type I","author":"Feldman","year":"2020","journal-title":"J Pediatr"},{"issue":"18","key":"10.1016\/j.spinee.2020.08.013_bib0055","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spinee.2020.08.013_bib0056","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human immune responses to adeno-associated virus (AAV) vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.spinee.2020.08.013_bib0057","doi-asserted-by":"crossref","first-page":"e00447","DOI":"10.1002\/prp2.447","article-title":"Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs","volume":"6","author":"Poirier","year":"2018","journal-title":"Pharmacol Res Perspect"},{"issue":"15","key":"10.1016\/j.spinee.2020.08.013_bib0058","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA)","volume":"61","author":"Ratni","year":"2018","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.spinee.2020.08.013_bib0059","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bcp.13786","article-title":"A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier","volume":"85","author":"Sturm","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"24","key":"10.1016\/j.spinee.2020.08.013_bib0060","doi-asserted-by":"crossref","first-page":"11021","DOI":"10.1021\/acs.jmedchem.8b01291","article-title":"Discovery of small molecule splicing modulators of survival motor neuron-2 (SMN2) for the treatment of spinal muscular atrophy (SMA)","volume":"61","author":"Cheung","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.spinee.2020.08.013_bib0061","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2020.01.003","article-title":"Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease","volume":"109","author":"Yeo","year":"2020","journal-title":"Pediatr Neurol"},{"issue":"3","key":"10.1016\/j.spinee.2020.08.013_bib0062","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/jcsm.12542","article-title":"Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy","volume":"11","author":"Zhou","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"10.1016\/j.spinee.2020.08.013_bib0063","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"18","key":"10.1016\/j.spinee.2020.08.013_bib0064","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1093\/hmg\/ddr275","article-title":"Temporal requirement for high SMN expression in SMA mice","volume":"20","author":"Le","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.spinee.2020.08.013_bib0065","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.nbd.2011.03.002","article-title":"Characterization of a commonly used mouse model of SMA reveals increased seizure susceptibility and heightened fear response in FVB\/N mice","volume":"43","author":"Gogliotti","year":"2011","journal-title":"Neurobiol Dis"},{"issue":"11","key":"10.1016\/j.spinee.2020.08.013_bib0066","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1172\/JCI124120","article-title":"Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment","volume":"129","author":"Ramos","year":"2019","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.spinee.2020.08.013_bib0067","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1172\/JCI72017","article-title":"Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation","volume":"124","author":"Kariya","year":"2014","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.spinee.2020.08.013_bib0068","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/00007632-199009000-00019","article-title":"Surgical treatment of scoliosis in a spinal muscular atrophy population","volume":"15","author":"Phillips","year":"1990","journal-title":"Spine (Phila Pa 1976)"},{"issue":"2","key":"10.1016\/j.spinee.2020.08.013_bib0069","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1212\/WNL.0000000000007742","article-title":"Natural course of scoliosis and lifetime risk of scoliosis surgery in spinal muscular atrophy","volume":"93","author":"Wijngaarde","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.spinee.2020.08.013_bib0070","first-page":"157","article-title":"Acute respiratory insufficiency as the initial clinical manifestation of spinal muscular atrophy","volume":"138","author":"Poets","year":"1990","journal-title":"Monatsschr Kinderheilkd"},{"issue":"7","key":"10.1016\/j.spinee.2020.08.013_bib0071","first-page":"918","article-title":"Anesthetic management of a patient with progressive spinal muscular atrophy","volume":"39","author":"Shime","year":"1990","journal-title":"Masui"},{"issue":"3","key":"10.1016\/j.spinee.2020.08.013_bib0072","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ajhg.2016.07.014","article-title":"The power of human protective modifiers: PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype","volume":"99","author":"Hosseinibarkooie","year":"2016","journal-title":"Am J Hum Genet"},{"issue":"21","key":"10.1016\/j.spinee.2020.08.013_bib0073","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.1093\/hmg\/ddv332","article-title":"Low levels of survival motor neuron protein are sufficient for normal muscle function in the SMNDelta7 mouse model of SMA","volume":"24","author":"Iyer","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"23","key":"10.1016\/j.spinee.2020.08.013_bib0074","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.1093\/hmg\/ddu350","article-title":"SMN regulates axonal local translation via miR-183\/mTOR pathway","volume":"23","author":"Kye","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1016\/j.spinee.2020.08.013_bib0075","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1172\/JCI71318","article-title":"Dysregulation of ubiquitin homeostasis and beta-catenin signaling promote spinal muscular atrophy","volume":"124","author":"Wishart","year":"2014","journal-title":"J Clin Invest"},{"issue":"48","key":"10.1016\/j.spinee.2020.08.013_bib0076","doi-asserted-by":"crossref","first-page":"19348","DOI":"10.1073\/pnas.1319280110","article-title":"Dysregulation of synaptogenesis genes antecedes motor neuron pathology in spinal muscular atrophy","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.spinee.2020.08.013_bib0077","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/jnnp-2019-321506","article-title":"Abnormal coagulation parameters are a common non-neuromuscular feature in patients with spinal muscular atrophy","volume":"91","author":"Wijngaarde","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8715","key":"10.1016\/j.spinee.2020.08.013_bib0078","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/0140-6736(90)93426-P","article-title":"Secondary metabolic defects in spinal muscular atrophy type II","volume":"336","author":"Harpey","year":"1990","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.spinee.2020.08.013_bib0079","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1399-0004.1990.tb03553.x","article-title":"Spinal muscular atrophy type I combined with atrial septal defect in three sibs","volume":"38","author":"Moller","year":"1990","journal-title":"Clin Genet"},{"issue":"2","key":"10.1016\/j.spinee.2020.08.013_bib0080","first-page":"177","article-title":"Hip dislocation in spinal muscular atrophy","volume":"75","author":"Granata","year":"1990","journal-title":"Chir Organi Mov"},{"issue":"11","key":"10.1016\/j.spinee.2020.08.013_bib0081","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/0883073820928784","article-title":"Clinical course in a patient with spinal muscular atrophy type 0 treated with nusinersen and onasemnogene abeparvovec","volume":"35","author":"Matesanz","year":"2020","journal-title":"J Child Neurol"},{"issue":"3","key":"10.1016\/j.spinee.2020.08.013_bib0082","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0960-8966(93)90061-N","article-title":"Spine surgery in spinal muscular atrophy: long-term results","volume":"3","author":"Granata","year":"1993","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.spinee.2020.08.013_bib0083","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/mus.26903","article-title":"Spinal muscular atrophy care in the COVID-19 pandemic era","volume":"62","author":"Veerapandiyan","year":"2020","journal-title":"Muscle Nerve"}],"container-title":["The Spine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1529943020310536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1529943020310536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T19:43:46Z","timestamp":1718480626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1529943020310536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":83,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1529943020310536"],"URL":"https:\/\/doi.org\/10.1016\/j.spinee.2020.08.013","relation":{},"ISSN":["1529-9430"],"issn-type":[{"value":"1529-9430","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapies for spinal muscular atrophy are likely changing the patient phenotype","name":"articletitle","label":"Article Title"},{"value":"The Spine Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.spinee.2020.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}